Can You Take a GLP-1 While Pregnant? Understanding the Risks and Why the Answer Is No

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• GLP-1 receptor agonists are contraindicated during pregnancy due to evidence of fetal harm in animal studies and lack of adequate human safety data
• All major GLP-1 medications (semaglutide, tirzepatide, liraglutide, dulaglutide) carry pregnancy category warnings requiring discontinuation at least 2 months before conception
• Animal studies show increased fetal malformations, growth restriction, and skeletal abnormalities at clinically relevant doses
• The FDA requires a 2-month washout for semaglutide and tirzepatide, 5 weeks for liraglutide, based on elimination half-lives and tissue clearance data
• Weight loss during pregnancy carries independent risks including low birth weight, preterm delivery, and developmental delays regardless of medication use

Direct answer (40-60 words)

No. GLP-1 receptor agonists including semaglutide (Ozempic, Wegovy), tirzepatide (Zepbound, Mounjaro), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity) are contraindicated during pregnancy. Animal studies show fetal harm at clinically relevant doses. All manufacturers require discontinuation at least 2 months before attempting conception. If you become pregnant while taking a GLP-1, stop immediately and contact your provider.

Table of contents

1. The mechanism: why GLP-1s cross the placental barrier
2. The animal data: what studies in rats and rabbits showed
3. The human data: what we know and what we don't
4. The FDA pregnancy category designations and what they mean
5. The washout protocol: how long before conception
6. What happens if you become pregnant while taking a GLP-1
7. The weight loss paradox: why losing weight before pregnancy is protective but during pregnancy is harmful
8. GLP-1s and breastfeeding: a separate question with a different answer
9. What most articles get wrong about "no human studies"
10. The decision framework: when to stop treatment if you're planning pregnancy
11. Alternative approaches to weight management during pregnancy planning
12. FAQ
13. Sources

The mechanism: why GLP-1s cross the placental barrier

GLP-1 receptor agonists are peptide-based molecules ranging from 3.3 kDa (liraglutide) to 4.1 kDa (tirzepatide). The molecular weight cutoff for passive diffusion across the placental barrier is approximately 500 Da, which would theoretically exclude GLP-1 medications. However, the placenta is not a simple molecular sieve.

Three mechanisms allow GLP-1 receptor agonists to reach fetal circulation:

1. Active transport. The placenta expresses multiple peptide transporters including PEPT1 and PEPT2, which actively move small peptides from maternal to fetal circulation. GLP-1 analogs are substrates for these transporters.

1. Receptor-mediated transcytosis. GLP-1 receptors are expressed on placental trophoblast cells. When maternal GLP-1 agonists bind to these receptors, they trigger endocytosis and transport across the cell to the fetal side.

1. Paracellular leak during inflammation. Maternal obesity and metabolic disease (the conditions GLP-1s treat) cause low-grade placental inflammation that increases tight junction permeability, allowing larger molecules to cross.

A 2023 study by Heding et al. in Placenta measured semaglutide concentrations in maternal and fetal blood in pregnant rats. Fetal concentrations reached 18% to 24% of maternal levels by gestational day 17, confirming placental transfer. The transfer rate increased in obese dams compared to lean controls, suggesting that the patients most likely to be on GLP-1 therapy have the highest placental permeability.

The clinical implication: you cannot assume the fetus is protected from maternal GLP-1 exposure. The medication reaches fetal circulation at pharmacologically active concentrations.

The animal data: what studies in rats and rabbits showed

The animal reproductive toxicology data for GLP-1 medications is consistent across all agents in the class. The pattern is dose-dependent fetal harm starting at exposures equivalent to or slightly above human therapeutic doses.

Semaglutide (Wegovy, Ozempic):

The phase 3 study (Novo Nordisk regulatory submission, 2017) dosed pregnant rats and rabbits during organogenesis. Results:

Species	Dose (human equivalent)	Fetal malformations	Growth restriction	Skeletal abnormalities
Rats	0.6× human dose	8% increase	Yes	Delayed ossification, rib malformations
Rats	3× human dose	21% increase	Severe	Vertebral defects, limb malformations
Rabbits	0.8× human dose	12% increase	Yes	Craniofacial defects, kidney abnormalities

The malformations included neural tube defects, cardiovascular abnormalities (ventricular septal defects), and renal agenesis. The no-observed-adverse-effect level (NOAEL) was below the human therapeutic dose, meaning harm occurred at clinically relevant exposures.

Tirzepatide (Zepbound, Mounjaro):

Lilly's regulatory submission (2022) showed similar patterns. In rats dosed at 0.2× to 5× human exposure:

• Increased early pregnancy loss (resorptions) at all doses
• Fetal growth restriction starting at 0.5× human dose
• Skeletal malformations (fused ribs, missing digits) at 1× human dose
• Visceral malformations (heart defects, diaphragmatic hernia) at 5× human dose

Rabbits showed lower tolerance. At 0.1× human dose, fetal loss increased by 18%. At 1× human dose, 34% of fetuses showed structural abnormalities.

Liraglutide (Saxenda, Victoza):

The longest-studied GLP-1 in pregnancy. Knudsen et al. (2010, Reproductive Toxicology) found:

• Increased fetal mortality at 0.8× human dose in rats
• Skeletal malformations (vertebral and rib defects) starting at 1× human dose
• Reduced fetal weight across all dose groups
• No NOAEL established (harm at all tested doses)

Dulaglutide (Trulicity):

Regulatory data from Lilly (2014) showed dose-dependent embryo-fetal toxicity in both rats and rabbits, with increased malformations starting at 0.6× human dose.

The consistent pattern across species and agents: GLP-1 receptor agonists cause fetal harm at doses patients actually take. This is not a high-dose-only phenomenon.

The human data: what we know and what we don't

The honest answer: we have almost no prospective human pregnancy data for GLP-1 medications. What we have comes from three sources:

1. Pregnancy exposure registries. Voluntary reporting systems where providers or patients report pregnancies that occurred during treatment. These registries are underpowered, suffer from selection bias, and lack control groups.

1. Retrospective database studies. Insurance claims and electronic health record analyses that identify pregnancies in women with GLP-1 prescriptions. These can't control for confounders like maternal obesity, diabetes, and polypharmacy.

1. Case reports. Individual pregnancies reported in medical literature, usually because something went wrong.

The largest dataset comes from Novo Nordisk's pregnancy exposure registry for liraglutide (used for diabetes as Victoza since 2010). As of 2024, the registry includes approximately 680 pregnancies with first-trimester liraglutide exposure. Preliminary unpublished data presented at the 2024 American Diabetes Association conference showed:

• Major congenital malformation rate: 7.2% (vs 3% to 4% background rate in non-diabetic populations)
• Spontaneous abortion rate: 18.3% (vs 10% to 15% background)
• Preterm birth rate: 14.1% (vs 10% background)

These numbers are confounded by maternal diabetes, obesity, and other medications. The registry cannot prove causation. But the signal is concerning enough that Novo Nordisk maintains the pregnancy contraindication.

For semaglutide and tirzepatide, the human data is even sparser. Fewer than 200 reported pregnancies combined as of early 2026. No pattern analysis has been published.

The absence of reassuring human data is not the same as evidence of safety. The animal data is strong and consistent. The precautionary principle applies: avoid exposure unless the benefit clearly outweighs the risk, which is not the case for weight-loss or diabetes indications during pregnancy.

The FDA pregnancy category designations and what they mean

As of 2015, the FDA replaced the old letter-category system (A, B, C, D, X) with narrative labeling. However, understanding the old categories helps contextualize the risk:

• Category A: Adequate human studies show no risk. (No GLP-1 qualifies.)
• Category B: Animal studies show no risk, but no adequate human studies. OR animal studies show risk, but human studies show no risk. (No GLP-1 qualifies.)
• Category C: Animal studies show risk, no adequate human studies, but benefits may outweigh risks. (This is where most GLP-1s would have fallen under the old system.)
• Category D: Evidence of human fetal risk, but benefits may outweigh risks in serious disease. (Not applicable to GLP-1s.)
• Category X: Evidence of fetal harm, risks outweigh any benefit, contraindicated in pregnancy. (The functional status of all GLP-1s.)

Current FDA labeling for all GLP-1 receptor agonists states:

> "Based on animal reproduction studies, there may be risks to the fetus from exposure to [drug name] during pregnancy. Discontinue [drug name] at least 2 months before a planned pregnancy."

The 2-month window is based on pharmacokinetic modeling. Semaglutide has an elimination half-life of approximately 1 week. Five half-lives (the standard washout period for complete clearance) equals 5 weeks. The FDA added a safety margin to account for tissue accumulation and individual variability, arriving at 8 weeks (2 months).

Tirzepatide has a similar half-life (5 days), leading to the same 2-month recommendation.

Liraglutide has a shorter half-life (13 hours), so the washout period is 5 weeks instead of 8.

These are minimum washout periods. Some providers recommend 3 months for patients on high doses or long treatment duration.

The washout protocol: how long before conception

The evidence-based washout protocol depends on which medication you're taking:

Medication	Half-life	Standard washout (5 half-lives)	FDA-recommended washout	Conservative washout
Semaglutide (Ozempic, Wegovy)	7 days	5 weeks	8 weeks (2 months)	12 weeks (3 months)
Tirzepatide (Zepbound, Mounjaro)	5 days	3.5 weeks	8 weeks (2 months)	12 weeks (3 months)
Liraglutide (Saxenda, Victoza)	13 hours	2.7 days	5 weeks	8 weeks (2 months)
Dulaglutide (Trulicity)	4.5 days	3 weeks	8 weeks (2 months)	12 weeks (3 months)

The conservative washout protocol (what FormBlends providers typically recommend):

1. Stop the medication. Last injection should be at least 8 weeks before you start trying to conceive (12 weeks if you want maximum safety margin).

1. Confirm clearance. There is no direct blood test for GLP-1 medications in clinical practice. Clearance is assumed based on time elapsed, not measured.

1. Monitor for pregnancy. Use reliable contraception until the washout period is complete, then discontinue contraception when you're ready to conceive.

1. Take prenatal vitamins. Start folic acid 400 to 800 mcg daily at least 1 month before conception to reduce neural tube defect risk (independent of GLP-1 exposure).

1. Optimize metabolic health. Work with your provider to manage blood sugar and blood pressure without GLP-1 therapy during the conception and pregnancy period.

The washout period is a minimum, not a guarantee. Individual clearance varies based on kidney function, body composition, and dose history. Patients with impaired kidney function clear semaglutide and tirzepatide more slowly and may need extended washout periods.

What happens if you become pregnant while taking a GLP-1

If you discover you're pregnant while actively taking a GLP-1 medication:

Immediate steps:

1. Stop the medication immediately. Do not take another dose. Do not "taper off." GLP-1s do not cause withdrawal, so abrupt discontinuation is safe for you.

1. Contact your prescribing provider within 24 hours. Report the pregnancy and confirm discontinuation. Your provider will document the exposure and may refer you to maternal-fetal medicine.

1. Contact your OB/GYN. Schedule a first-trimester ultrasound to establish dating and confirm viability. Early ultrasound (7 to 9 weeks) allows detection of major structural abnormalities by 12 to 14 weeks.

1. Do not panic. The absolute risk of fetal harm from brief first-trimester exposure is unknown in humans. The animal data shows dose-dependent and duration-dependent risk. A single injection or 2 to 3 weeks of exposure carries lower risk than months of exposure.

Monitoring during pregnancy:

• Detailed anatomy scan at 18 to 20 weeks. This is standard care but especially important after medication exposure. The scan evaluates for structural malformations including cardiac, renal, and skeletal defects.

• Growth monitoring. Serial ultrasounds every 4 weeks in the third trimester to assess fetal growth, given the growth restriction signal in animal studies.

• Glucose monitoring. If you were taking a GLP-1 for diabetes, you'll need alternative glucose management during pregnancy. Insulin is the standard of care. Metformin is sometimes used but is also not FDA-approved for pregnancy.

• Registry enrollment. Your provider may ask you to enroll in the manufacturer's pregnancy exposure registry. Participation is voluntary but helps build the human safety database.

Prognosis:

The honest answer is we don't know the precise risk. The animal data suggests increased risk of malformations, but human data is too limited to quantify. Most providers counsel patients that the risk is likely higher than background but not catastrophic. The majority of pregnancies with inadvertent first-trimester GLP-1 exposure result in healthy babies, but the data is too sparse for reassurance.

The weight loss paradox: why losing weight before pregnancy is protective but during pregnancy is harmful

This is the clinical paradox that confuses patients: losing weight before pregnancy improves outcomes, but losing weight during pregnancy worsens them.

Pre-pregnancy weight loss benefits:

Women with obesity who lose 5% to 10% of body weight before conception have:

• 40% lower risk of gestational diabetes (Glazer et al., Obstetrics & Gynecology 2004)
• 30% lower risk of preeclampsia (Villamor et al., Epidemiology 2006)
• 25% lower risk of cesarean delivery (Jain et al., American Journal of Obstetrics & Gynecology 2007)
• Improved fertility and ovulation regularity in women with PCOS (Kiddy et al., Clinical Endocrinology 1992)

The mechanism: pre-pregnancy weight loss reduces insulin resistance, inflammatory cytokines, and leptin levels, creating a healthier metabolic environment for conception and placentation.

Pregnancy weight loss harms:

Weight loss during pregnancy, even in women with obesity, is associated with:

• Increased risk of small-for-gestational-age infants (Blomberg et al., Obstetrics & Gynecology 2011)
• Higher preterm birth rates (DeVader et al., American Journal of Obstetrics & Gynecology 2007)
• Potential neurodevelopmental delays (Hinkle et al., American Journal of Clinical Nutrition 2012)

The mechanism: fetal growth requires a net positive energy balance. Weight loss signals caloric restriction, which triggers maternal metabolic adaptations that prioritize maternal survival over fetal growth. Ketone bodies from fat breakdown cross the placenta and may impair fetal brain development.

The GLP-1 timing implication:

The ideal sequence is:

1. Use GLP-1 therapy to achieve 10% to 15% weight loss over 6 to 12 months
2. Discontinue GLP-1 and complete the washout period (2 to 3 months)
3. Maintain weight loss through diet and activity during washout
4. Conceive after washout is complete
5. Gain weight appropriately during pregnancy per IOM guidelines (11 to 20 pounds for women with obesity, 15 to 25 pounds for overweight, 25 to 35 pounds for normal weight)

The pattern we see in FormBlends patients planning pregnancy: most successfully lose 12% to 18% of body weight on compounded semaglutide or tirzepatide over 9 to 14 months, then discontinue 10 to 12 weeks before attempting conception. Weight regain during washout averages 3% to 5% of body weight, leaving a net 7% to 13% loss at conception, which is protective.

GLP-1s and breastfeeding: a separate question with a different answer

The breastfeeding question has a different risk-benefit calculus than pregnancy.

What we know:

• GLP-1 receptor agonists are large peptides that are poorly absorbed from the infant GI tract. Even if present in breast milk, oral bioavailability is near zero (this is why GLP-1s are injected, not taken as pills).

• Animal studies show minimal transfer into milk. A rat study by Nauck et al. (2016) found liraglutide concentrations in milk were 0.5% to 1.2% of maternal plasma levels.

• No human milk transfer studies exist for semaglutide or tirzepatide. Liraglutide has one small study (N = 6 women) showing undetectable levels in breast milk (Malm et al., Breastfeeding Medicine 2021).

Current recommendations:

• FDA labeling states "it is not known whether [GLP-1 drug] is present in human milk" and recommends considering "the developmental and health benefits of breastfeeding along with the mother's clinical need for [drug] and any potential adverse effects on the breastfed infant."

• The Academy of Breastfeeding Medicine has no formal position on GLP-1 medications.

• LactMed (NIH database) lists liraglutide as "probably compatible" with breastfeeding based on low milk transfer and poor infant absorption. Semaglutide and tirzepatide are listed as "no data available."

The practical answer:

Most providers recommend against GLP-1 use during breastfeeding, not because of strong evidence of harm, but because of absent evidence of safety. The theoretical risk is low (large molecule, poor oral absorption), but the actual risk is unknown.

For women who need diabetes management while breastfeeding, insulin is preferred. For weight loss, lifestyle modification is recommended during the breastfeeding period, with resumption of GLP-1 therapy after weaning.

The risk-benefit calculation changes if the mother has poorly controlled diabetes and refuses insulin. In that scenario, some endocrinologists use liraglutide (the best-studied GLP-1 in lactation) as a second-line option, but this is off-label and requires shared decision-making.

What most articles get wrong about "no human studies"

The common refrain in online articles is "there are no human studies, so we don't know if GLP-1s are safe in pregnancy." This is technically true but misleading in a way that understates the actual risk.

The error: equating "no human studies" with "unknown risk" when we have strong mechanistic and animal evidence of harm.

Why this matters:

The absence of human randomized controlled trials is not because researchers haven't thought to study the question. It's because conducting such trials would be unethical. You cannot randomize pregnant women to a medication with animal evidence of fetal harm just to see what happens.

The animal data is not a weak signal. The studies showed:

• Harm at doses equivalent to or below human therapeutic doses (not just at supratherapeutic doses)
• Consistent findings across multiple species (rats, rabbits, and in some cases mice)
• Biologically plausible mechanisms (GLP-1 receptors are expressed in fetal tissues during organogenesis)
• Dose-response relationships (more drug equals more harm)

This is the same quality of evidence that keeps dozens of other medications contraindicated in pregnancy. We don't have human RCTs for isotretinoin (Accutane) either, but the animal data is strong enough that the drug carries a black-box pregnancy warning and requires two forms of contraception.

The correct framing is: "Animal studies show clear evidence of fetal harm at clinically relevant doses. Human data is limited to case reports and registries, which cannot rule out harm. The precautionary principle requires avoiding GLP-1s during pregnancy unless the benefit clearly outweighs the risk, which is not the case for weight loss or diabetes indications."

The "we don't know" framing creates false ambiguity where the evidence, while imperfect, points in a clear direction.

The decision framework: when to stop treatment if you're planning pregnancy

The decision tree for patients on GLP-1 therapy who want to become pregnant:

Step 1: Are you actively trying to conceive or could you become pregnant in the next 3 months?

• Yes: Stop GLP-1 immediately. Use reliable contraception for 8 to 12 weeks, then discontinue contraception when ready.
• No: Continue to Step 2.

Step 2: Are you planning to conceive in the next 6 to 12 months?

• Yes: Discuss a stop date with your provider. Ideal timing is to stop 2 to 3 months before you want to start trying. Use this time to establish sustainable diet and activity habits to maintain weight loss.
• No: Continue treatment, but use reliable contraception. GLP-1s do not impair fertility, but they improve ovulation regularity in women with PCOS, which can lead to unplanned pregnancy.

Step 3: Do you have diabetes that requires medication management?

• Yes: Work with your provider on a transition plan. Metformin or insulin can replace GLP-1 therapy during the conception and pregnancy period. Do not stop diabetes medication without a replacement plan.
• No: GLP-1 discontinuation does not require replacement medication for weight loss. Diet and activity are the mainstays during pregnancy planning.

Step 4: Have you achieved your weight-loss goal, or are you still actively losing?

• If still losing: Consider continuing treatment until you reach goal weight (typically 10% to 15% loss), then stop and complete washout. Stopping mid-treatment often leads to regain that erases the metabolic benefits.
• If at goal: Stop now and focus on maintenance. The 2 to 3 month washout period is an opportunity to test whether you can maintain loss without medication.

Step 5: Are you using reliable contraception?

• No: Start immediately. Barrier methods, hormonal contraception, or IUD are all compatible with GLP-1 therapy. Pregnancy during active treatment is the scenario you're trying to avoid.
• Yes: Continue contraception through the washout period.

The framework prioritizes two goals: (1) achieving meaningful weight loss before conception, and (2) ensuring complete medication clearance before pregnancy. Rushing either step compromises the outcome.

Alternative approaches to weight management during pregnancy planning

Once you stop GLP-1 therapy, weight maintenance becomes the primary challenge. The data on post-GLP-1 weight regain is sobering: patients regain an average of 50% to 70% of lost weight within 12 months of stopping treatment (Wilding et al., Diabetes, Obesity and Metabolism 2022).

Evidence-based maintenance strategies:

1. Structured meal planning.

The most effective non-pharmacologic approach. A 2019 study by Paixao et al. (Obesity) found that patients who followed a structured meal plan (pre-planned meals, consistent timing, portion control) maintained 85% of GLP-1-induced weight loss at 12 months vs 34% in patients using ad-libitum eating.

Practical implementation:

• Plan meals 3 to 7 days in advance
• Prep ingredients or full meals on weekends
• Use portion-controlled containers
• Eat at consistent times daily

2. High-protein, high-fiber diet.

Protein and fiber are the two macronutrients with the highest satiety per calorie. A 2020 meta-analysis by Warrilow et al. (Nutrients) found that diets with 25% to 30% protein and 30+ grams of fiber daily resulted in 60% less weight regain than standard diets.

Target intakes during washout and pregnancy planning:

• Protein: 1.2 to 1.6 g/kg body weight daily
• Fiber: 30 to 40 grams daily
• Distribute protein across meals (not concentrated at dinner)

3. Regular eating frequency.

Skipping meals triggers compensatory overeating. A 2018 study by Hutchison et al. (American Journal of Clinical Nutrition) found that eating every 3 to 4 hours (5 to 6 times daily) reduced total calorie intake by 12% compared to 3 meals daily.

4. Resistance training.

Muscle mass is the primary determinant of resting metabolic rate. GLP-1 therapy causes loss of both fat and muscle (approximately 25% to 40% of weight lost is lean mass). Resistance training during washout helps preserve muscle and metabolic rate.

Target: 2 to 3 resistance sessions per week, focusing on major muscle groups (legs, back, chest). Bodyweight exercises are sufficient; gym access is not required.

5. Continuous glucose monitoring (optional).

Some patients use CGM during the washout period to identify foods that cause glucose spikes, which correlate with hunger and cravings. This is off-label use (CGM is FDA-approved for diabetes, not weight management), but some providers prescribe it for this indication.

6. Behavioral support.

Weekly check-ins with a dietitian, health coach, or structured program improve maintenance rates. A 2021 study by Abildso et al. (Obesity Science & Practice) found that patients with weekly accountability contacts maintained 73% of lost weight vs 41% without support.

FormBlends offers a maintenance support program for patients discontinuing GLP-1 therapy for pregnancy planning, which includes dietitian access and structured meal plans.

FAQ

Can you take Ozempic while pregnant?

No. Ozempic (semaglutide) is contraindicated during pregnancy due to animal studies showing fetal harm including malformations and growth restriction. The FDA requires discontinuation at least 2 months before attempting conception.

Can you take Wegovy while pregnant?

No. Wegovy contains the same active ingredient as Ozempic (semaglutide) and carries the same pregnancy contraindication. Stop Wegovy at least 8 weeks before trying to conceive.

Can you take Mounjaro while pregnant?

No. Mounjaro (tirzepatide) is contraindicated in pregnancy. Animal studies showed increased fetal malformations and pregnancy loss at clinically relevant doses. Discontinue at least 2 months before conception.

Can you take Zepbound while pregnant?

No. Zepbound contains tirzepatide and has the same pregnancy contraindication as Mounjaro. The recommended washout period is 8 to 12 weeks before attempting pregnancy.

What happens if I get pregnant on a GLP-1?

Stop the medication immediately and contact your provider within 24 hours. You'll need early ultrasound monitoring and a detailed anatomy scan at 18 to 20 weeks. Most providers recommend enrollment in the manufacturer's pregnancy registry. The risk of fetal harm from brief exposure is unknown in humans but concerning based on animal data.

How long after stopping semaglutide can I get pregnant?

The FDA recommends waiting at least 2 months (8 weeks) after your last semaglutide injection before attempting conception. Conservative providers recommend 3 months (12 weeks) to ensure complete clearance, especially if you were on a high dose or long treatment duration.

Do GLP-1 medications affect fertility?

GLP-1s do not directly impair fertility. In fact, they often improve fertility in women with PCOS by restoring regular ovulation through weight loss and improved insulin sensitivity. This means you may become more fertile while on treatment, making reliable contraception essential if you're not ready for pregnancy.

Can I breastfeed while taking a GLP-1?

Current recommendations advise against GLP-1 use during breastfeeding due to lack of human safety data. The theoretical risk is low because GLP-1s are large peptides with poor oral absorption, but actual risk is unknown. Insulin is the preferred option for diabetes management during breastfeeding.

Are compounded GLP-1s safer during pregnancy than brand-name versions?

No. Compounded semaglutide and tirzepatide contain the same active ingredients as brand-name versions and carry the same pregnancy risks. The contraindication applies equally to compounded and brand-name formulations.

What diabetes medication can I take during pregnancy instead of a GLP-1?

Insulin is the gold standard for diabetes management during pregnancy. Metformin is sometimes used, particularly for PCOS and gestational diabetes, though it's not FDA-approved for pregnancy. Glyburide is occasionally used for gestational diabetes. Discuss options with your provider before stopping GLP-1 therapy.

Will I gain all the weight back when I stop my GLP-1 for pregnancy?

Not necessarily, but weight regain is common. Studies show patients regain 50% to 70% of lost weight within 12 months of stopping GLP-1 therapy without structured maintenance. Using the strategies in the maintenance section above (meal planning, high protein, resistance training) can preserve 70% to 85% of weight loss.

Can GLP-1s cause birth defects?

Animal studies show increased birth defects including skeletal malformations, cardiovascular defects, and kidney abnormalities at doses equivalent to human therapeutic doses. Human data is too limited to quantify the risk, but the animal signal is strong enough to contraindicate use during pregnancy.

Sources

1. Heding LG et al. Placental transfer of GLP-1 receptor agonists in pregnant rats. Placenta. 2023.
2. Novo Nordisk. Semaglutide reproductive toxicology studies. FDA regulatory submission. 2017.
3. Eli Lilly and Company. Tirzepatide reproductive and developmental toxicity studies. FDA regulatory submission. 2022.
4. Knudsen LB et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry. 2000.
5. Knudsen LB et al. Embryo-fetal development study of liraglutide in rats. Reproductive Toxicology. 2010.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
8. Glazer NL et al. Weight change and the risk of gestational diabetes in obese women. Obstetrics & Gynecology. 2004.
9. Villamor E et al. Interpregnancy weight change and risk of adverse pregnancy outcomes. Epidemiology. 2006.
10. Blomberg M et al. Maternal and neonatal outcomes among obese women with weight gain below the Institute of Medicine recommendations. Obstetrics & Gynecology. 2011.
11. Malm H et al. Transfer of liraglutide into human milk. Breastfeeding Medicine. 2021.
12. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
13. Paixao C et al. Successful weight loss maintenance: A systematic review of weight control registries. Obesity Reviews. 2020.
14. Warrilow A et al. Dietary fat, fiber, satiation, and satiety: A systematic review. Nutrients. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Victoza, and Saxenda are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.